Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

6 november 2019 uppdaterad av: Chong Kun Dang Pharmaceutical

An Open-label, Rendomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-387 in Healthy Subjects.

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-387

Studieöversikt

Detaljerad beskrivning

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-387 in helalthy subjects.

Studietyp

Interventionell

Inskrivning (Faktisk)

58

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Seongbuk-Gu
      • Seoul, Seongbuk-Gu, Korea, Republiken av
        • Korea University Anam Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

19 år till 45 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Healthy adult older than 19 years and less than 45 years at the time of screening.
  2. BMI 18.5~29.9 kg/m2 and body weight more than 50kg.
  3. Subjects who have consented to the use of appropriate double- pregnancy contraceptive methods up to one months after the last investigational product and not to provide sperm for men.
  4. Subjects who sign on an informed consent form willingly.

Exclusion Criteria:

  1. Subjects who have a clinically significant disease or medical history such as respiratory, hepatic, kidneys, blood, gastrointestinal, endocrine, immune system, skin, nervous and mental disease.
  2. Subjects who have acute disease within 28 days prior to the first administration.
  3. Subjects who have history that may affect the ADME.
  4. Subjects who have medical history or medical abuse history of hypersensitivity from SGLT inhibitors or Biguanides including Metformin or other medications(Aspirin, Antibiotics etc.).
  5. Subjects who have clinically significant chronic disease.
  6. Subjects with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose mal-absorption.
  7. Subjects whose laboratory test result are same as below;

    • AST,ALT > UNL(Upper Normal Limit)x3
    • Fasting glucose level out of 70-125mg/dl
    • Creatinine clearance is lower than 80mL/min which is calcuated by Cockcroft-Gault formulation.
    • QT>450msec
    • Positive urine hCG(female).
  8. Subjects whoes blood pressure exceeds out of normal range as below at screening.

    • SBP : over 100mmHg, under 160mmHg
    • DBP : over 60mmHg, under 100mmHg
  9. Subjects who have been found to be positive in serological tests(HBs antigen, HCV antibody and HIV antibody).
  10. Subjects who took ETC(Ethical Drug), oriental medicine within 2 weeks prior to the first administration of investigational products.
  11. Subjects who took OTC(Over-the-counter Drug, including korean galenical drug) within 10 days prior to the first administration of investigational products.
  12. Subjects who have allergic disease which has clinical significance(But, light allergic rhinitis and ligth allergic dermatitis which do not need medication is exceptional).
  13. Subjects who can not eat standard meals provided by the institution.
  14. Subjects who donated whole blood within 60 days, donated the blood components within 20 days prior to the first administration of investigational products.
  15. Subjects who received blood transfusion within 30 days prior to the first administration of investigational products.
  16. Subjects who were participated in the other clinical trial within 90 days prior to the first administration of investigational products.
  17. Subjects who took medication for the induction and inhibition of metabolizing enzymes such as barbiturate drugs within 6months prior to the first administration of investigational products.
  18. Subjects who have had abnormal diets that can affect the ADME of the drug within 30 days prior to the first administration of investigational products. (Ingestion of grapefruit juice>1L/day or Caffein>5Cups/day).
  19. Subjects who have took regular alcohol(alcohol>30g/day) prior to the first administration of investigational products.
  20. Subjects who smoked more than 10 cigarettes per day prior 3months to the first administration of investigational products or cannot discontinue smoking during the clinical trial.
  21. Subjects who is determined unsuitable to participate in this clinical trial by the investigator.
  22. Lactating Women.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: PartA, Treatment-1
Period 1 : Reference drug Period 2 : Test drug
Once a day. Under fasting condition
Andra namn:
  • PartA, Test(CKD-387 10/500mg)
Experimentell: PartA, Treatment-2
Period 1 : Test drug Period 2 : Reference drug
Once a day. Under fasting condition
Andra namn:
  • PartA, Test(CKD-387 10/500mg)
Experimentell: PartB, Treatment-1
Period 1 : Reference drug Period 2 : Test drug
Once a day. Under fed condition
Andra namn:
  • PartB, Test(CKD-387 10/500mg)
Experimentell: PartB, Treatment-2
Period 1 : Test drug Period 2 : Reference drug
Once a day. Under fed condition
Andra namn:
  • PartB, Test(CKD-387 10/500mg)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part A : Cmax under fasting condition
Tidsram: 0(predose)~48 hours
Maximum concentration of the dapagliflozin
0(predose)~48 hours
Part A : Cmax under fasting condition
Tidsram: 0(predose)~48 hours
Maximum concentration of the metformin
0(predose)~48 hours
Part A : AUClast under fasting condition
Tidsram: 0(predose)~48 hours
Area Under Curve(last) of the dapagliflozin
0(predose)~48 hours
Part A : AUClast under fasting condition
Tidsram: 0(predose)~48 hours
Area Under Curve(last) of the metformin
0(predose)~48 hours
Part B : Cmax under fed condition
Tidsram: 0(predose)~48 hours
Maximum concentration of the metformin
0(predose)~48 hours
Part B : AUClast under fed condition
Tidsram: 0(predose)~48 hours
Area Under Curve(last) of the metformin
0(predose)~48 hours

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Part A : AUCinf under fasting condition
Tidsram: 0(predose)~48 hours
Area Under Curve(infinit) of the dapagliflozin
0(predose)~48 hours
Part A : AUCinf under fasting condition
Tidsram: 0(predose)~48 hours
Area Under Curve(infinit) of the metformin
0(predose)~48 hours
Part A : Tmax under fasting condition
Tidsram: 0(predose)~48 hours
Time of maximum concentration of the dapagliflozin
0(predose)~48 hours
Part A : Tmax under fasting condition
Tidsram: 0(predose)~48 hours
Time of maximum concentration of the metformin
0(predose)~48 hours
Part A : t1/2 under fasting condition
Tidsram: 0(predose)~48 hours
Half life of the dapagliflozin
0(predose)~48 hours
Part A : t1/2 under fasting condition
Tidsram: 0(predose)~48 hours
Half life of the metformin
0(predose)~48 hours
Part B : AUCinf under fed condition
Tidsram: 0(predose)~48 hours
Area Under Curve(infinit) of the metformin
0(predose)~48 hours
Part B : Tmax under fed condition
Tidsram: 0(predose)~48 hours
Time of Maximum concentration of the metformin
0(predose)~48 hours
Part B : t1/2 under fed condition
Tidsram: 0(predose)~48 hours
Half life of the metformin
0(predose)~48 hours

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Ji-Young Park, M.D, Ph.D, Korea University Anam Hospital / Seoul, Seongbuk-Gu, South Korea

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

6 augusti 2019

Primärt slutförande (Faktisk)

30 augusti 2019

Avslutad studie (Faktisk)

2 oktober 2019

Studieregistreringsdatum

Först inskickad

6 november 2019

Först inskickad som uppfyllde QC-kriterierna

6 november 2019

Första postat (Faktisk)

7 november 2019

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

7 november 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

6 november 2019

Senast verifierad

1 november 2019

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera